Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL
Both CAR-Ts Offer Survival Gains, With Longer Data For Kite’s Product
Data at ASH show CAR-T therapies may replace standard of care in an earlier line of large B-cell lymphoma with similar response rates and event-free survival for Kite’s established Yescarta and Bristol’s newer Breyanzi.
You may also be interested in...
Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma
Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.
Bristol’s Growth Plan Faces First Test In 2022
Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Pfizer buys into inflammation and immunology; bispecifics and CAR-Ts in the spotlight at ASH; Lilly looks to volume-driven growth; and Novavax talks about diversity in clinical trials.